Hugo Arasanz

2.6k citations
57 papers · 1.8k indexed · h-index 20
Topics
Cancer Immunotherapy and Biomarkers (30 papers)Immunotherapy and Immune Responses (18 papers)CAR-T cell therapy research (14 papers)
Partner nations
SpainUnited KingdomItaly

In The Last Decade

Hugo Arasanz

53 papers receiving 1.7k citations

Peers

Hugo Arasanz
Comparison fields: 5 of 90
  • Oncology 1.3k
  • Immunology 940
  • Molecular Biology 354
  • Pulmonary and Respiratory Medicine 251
  • Cancer Research 140
Replace Lawrence P. Andrews with:
Lawrence P. Andrews United States
Miren Zuazo Spain
Kota Iwahori Japan
Viktor Fleming Germany
María Gato Spain
Kim C. Ohaegbulam United States
Lucy Boyce Kennedy United States
Guangbo Zhang China
Hampartsoum B. Barsoumian United States
Hugo Arasanz relative to Lawrence P. Andrews United States Lawrence P. Andrews's profile →
Citations per field
00.5×1.5×
Lawrence P. Andrews · 1×
Citations per year

Countries citing papers authored by Hugo Arasanz

Since Specialization
Citations

This map shows the geographic impact of Hugo Arasanz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hugo Arasanz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hugo Arasanz more than expected).

Fields of papers citing papers by Hugo Arasanz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hugo Arasanz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hugo Arasanz. The network helps show where Hugo Arasanz may publish in the future.

Co-authorship network of co-authors of Hugo Arasanz

This figure shows the co-authorship network connecting the top 25 collaborators of Hugo Arasanz. A scholar is included among the top collaborators of Hugo Arasanz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hugo Arasanz. Hugo Arasanz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2 11
3 4
4 2
5 11
6 6
7 1
8 11
9 14
10 26
11 11
12 16
13 9
14 20
15 7
16 58
17 27
18 54
19 143
20 62

About Hugo Arasanz

Hugo Arasanz is a scholar working on Oncology, Immunology and Cancer Research, having authored 57 papers that have together received 1.8k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (30 papers), Immunotherapy and Immune Responses (18 papers) and CAR-T cell therapy research (14 papers). The work is most often cited by research in Oncology (1.3k citations), Immunology (940 citations) and Cancer Research (140 citations). Hugo Arasanz has collaborated with scholars based in Spain, United Kingdom and Italy. Frequent co-authors include Grazyna Kochan, David Escors, Miren Zuazo, María Gato, Ruth Vera, Ana Bocanegra, María Ibáñez-Vea, G. Fernández-Hinojal, Luisa Chocarro and María Jesús García-Granda. Their work appears in journals such as Scientific Reports, International Journal of Molecular Sciences and British Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026